DPYSL5

Across TCGA pan-cancer cohorts, DPYSL5 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated DPYSL5 data layer compared with 22 for mass-spec protein and 5 for mass-spec protein.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where higher DPYSL5 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DPYSL5 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.

BLCA, COAD, and SKCM are the cancer types where DPYSL5 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BLCA	OS	Median	III,IV	0.069	0.582	<.001	12	view →
COAD	OS	Median	III,IV	0.157	0.791	.001	8	view →
SKCM	DFS	Median	IV	0.040	0.454	.028	6	view →
LUSC	DFS	Median	All	0.748	0.362	.031	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →
LIHC	DFS	Median	II,III,IV	0.138	0.430	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

DPYSL5–BLCA (OS)

Open the BLCA breakdown →